文献速递淋巴瘤造血干细胞移植与细胞治疗

高危霍奇金淋巴瘤患者接受异基因造血干细胞移植作为首次移植的长期结局:来自EBMT淋巴瘤工作组的一项回顾性分析

Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT.
PubMed 文献 · Br J Haematol · 2021-11-08

该回顾性分析纳入190例以异基因造血干细胞移植作为首次移植的高危霍奇金淋巴瘤患者,其中63%既往接受过维布妥昔单抗和/或检查点抑制剂。中位随访58个月后,3年总生存率为58%、无进展生存率为41%。多变量分析显示,清髓性预处理联合T细胞去除的NRM与减低强度预处理相当,但复发风险更低,从而带来显著更优的OS和PFS。

要点

  • 190例高危霍奇金淋巴瘤患者以异基因移植作为首次移植,3年OS为58%、PFS为41%。
  • 100天II-IV级急性GVHD累积发生率为25%,3年慢性GVHD累积发生率为38%。
  • 清髓性预处理联合T细胞去除可能为高危霍奇金淋巴瘤异基因移植的最佳选择。

核心结论

  • 在高危霍奇金淋巴瘤且适合异基因造血干细胞移植的患者中,清髓性预处理联合T细胞去除可能是最佳选择。

研究设计与样本

  • 回顾性分析,纳入190例以异基因造血干细胞移植作为首次移植的高危霍奇金淋巴瘤患者。
  • 63%的患者既往接受过维布妥昔单抗和/或检查点抑制剂。
  • 70例(37%)接受无关供者异基因造血干细胞移植,99例(51%)接受清髓性预处理,60%接受体内T细胞去除/去除T细胞移植物。

主要发现

  • 100天II-IV级急性GVHD累积发生率为25%,3年慢性GVHD累积发生率为38%。
  • 3年非复发死亡累积发生率为21%,复发率为38%。
  • 中位随访58个月后,3年总生存率为58%,无进展生存率为41%。
  • 多变量分析显示,与联合或不联合T细胞去除的减低强度预处理相比,清髓性预处理联合T细胞去除的非复发死亡相似,且复发风险更低,带来显著更优的OS和PFS。
  • 清髓性预处理不联合T细胞去除与更高的非复发死亡和更差的生存结局相关。

临床怎么用

  • 作者认为,在高危霍奇金淋巴瘤且适合异基因造血干细胞移植的患者中,清髓性预处理联合T细胞去除可能是最佳选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We analysed long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation (allo-HSCT) as a first transplant for high-risk Hodgkin lymphoma (HL). One hundred and ninety patients were included in this study, 63% of them had previously received brentuximab vedotin and/or checkpoint inhibitors. Seventy patients (37%) received an unrelated donor allo-HSCT, 99 (51%) had myeloablative conditioning (MAC) and 60% had in vivo T-cell/depleted grafts (TCD). The 100-day cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 25% and the 3-year CI of chronic GVHD was 38%. The 3-year CI of non-relapse mortality (NRM) and relapse rate were 21% and 38% respectively. After a median follow-up of 58 months, 3-year overall survival (OS) and progression-free survival (PFS) were 58% and 41% respectively. Multivariate analysis showed that, in comparison to reduced-intensity conditioning regimens with or without TCD, MAC using TCD had similar NRM and a lower risk of relapse leading to significantly better OS and PFS. MAC without TCD was associated with higher NRM and worse survival outcomes. These results suggest that in patients with high-risk HL and candidates of allo-HSCT, a MAC strategy with TCD might be the best option.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gutiérrez-García G, Martínez C, Boumendil A, et al. Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT. Br J Haematol. 2021. PMID: 34750806. doi:10.1111/bjh.17939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。